Management of COPD Patients With BoraCare® Remote Monitoring Solution Including BVS3 Early Detection Score for COPD Exacerbations
NCT06523140 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 380
Last updated 2025-08-22
Summary
The goal of this clinical trial is to demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations (experimental group) compared to conventional follow-up alone (control group) on the total number of hospital days per patient for respiratory deterioration over 12 months of follow-up.
The main question it aims to answer is: Does remote monitoring of COPD patients reduce the average annual length of hospitalization for exacerbations of COPD patients?
All participants will benefit a conventional clinical follow-up.
Participants in experimental group will also benefit from the Bora care remote monitoring system.
Conditions
Interventions
- DEVICE
-
Boracare remote monitoring solution
Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
collaborator OTHER -
Biosency
lead INDUSTRY
Principal Investigators
-
Nicolas ROCHE, MD · Hôpital Cochin, AP-HP
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-20
- Primary Completion
- 2027-12-31
- Completion
- 2027-12-31
Countries
- France
Study Locations
More Related Trials
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
NCT02231424 ·Status: COMPLETED
-
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
NCT03836677 ·Status: COMPLETED ·Phase: PHASE3
-
ANTES B+ Clinical Trial
NCT06282861 ·Status: TERMINATED ·Phase: PHASE4
-
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
NCT01760304 ·Status: TERMINATED ·Phase: PHASE4
-
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01323621 ·Status: COMPLETED ·Phase: PHASE3
-
Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD
NCT02567214 ·Status: COMPLETED ·Phase: PHASE4
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00622635 ·Status: COMPLETED ·Phase: PHASE3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
NCT01323660 ·Status: COMPLETED ·Phase: PHASE3
-
Budesonide / Formoterol in Treatment of Exacerbations of COPD
NCT00239278 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
NCT00267917 ·Status: COMPLETED ·Phase: PHASE4
-
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
NCT01794780 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))
NCT01342913 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT02172352 ·Status: COMPLETED ·Phase: PHASE2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00606684 ·Status: COMPLETED ·Phase: PHASE2
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02232594 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
NCT02371629 ·Status: COMPLETED ·Phase: PHASE4
-
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
NCT01712516 ·Status: COMPLETED ·Phase: PHASE3
-
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
NCT00742248 ·Status: COMPLETED ·Phase: PHASE2
-
Exacerbations and Their Outcomes International (EXACOS International)
NCT04928417 ·Status: COMPLETED
-
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
NCT01040689 ·Status: COMPLETED ·Phase: PHASE3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
NCT01328444 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler
NCT01257048 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD
NCT03081156 ·Status: COMPLETED ·Phase: PHASE4
-
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
NCT06712563 ·Status: RECRUITING
-
Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02173782 ·Status: COMPLETED ·Phase: PHASE3